IL183930A0 - Use of cladribine for preparation of pharmaceutical compositions - Google Patents
Use of cladribine for preparation of pharmaceutical compositionsInfo
- Publication number
- IL183930A0 IL183930A0 IL183930A IL18393007A IL183930A0 IL 183930 A0 IL183930 A0 IL 183930A0 IL 183930 A IL183930 A IL 183930A IL 18393007 A IL18393007 A IL 18393007A IL 183930 A0 IL183930 A0 IL 183930A0
- Authority
- IL
- Israel
- Prior art keywords
- cladribine
- preparation
- pharmaceutical compositions
- pharmaceutical
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63866904P | 2004-12-22 | 2004-12-22 | |
| EP04106909 | 2004-12-22 | ||
| PCT/EP2005/056954 WO2006067141A1 (en) | 2004-12-22 | 2005-12-20 | Cladribine regimen for treating multiple sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL183930A0 true IL183930A0 (en) | 2007-10-31 |
Family
ID=36227798
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL183930A IL183930A0 (en) | 2004-12-22 | 2007-06-14 | Use of cladribine for preparation of pharmaceutical compositions |
| IL212421A IL212421A (en) | 2004-12-22 | 2011-04-17 | Use of cladribine for the preparation of multiple sclerosis therapy |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL212421A IL212421A (en) | 2004-12-22 | 2011-04-17 | Use of cladribine for the preparation of multiple sclerosis therapy |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US7713947B2 (OSRAM) |
| EP (7) | EP2805723B1 (OSRAM) |
| JP (7) | JP5795456B2 (OSRAM) |
| KR (1) | KR20070091662A (OSRAM) |
| AR (1) | AR052830A1 (OSRAM) |
| AU (2) | AU2005318190B2 (OSRAM) |
| BR (1) | BRPI0517132B8 (OSRAM) |
| CA (2) | CA2588966C (OSRAM) |
| CY (3) | CY1112614T1 (OSRAM) |
| DK (3) | DK2805723T3 (OSRAM) |
| EA (1) | EA015799B1 (OSRAM) |
| ES (2) | ES2921858T3 (OSRAM) |
| FI (1) | FI4070800T3 (OSRAM) |
| FR (1) | FR18C1008I2 (OSRAM) |
| HR (1) | HRP20120228T1 (OSRAM) |
| HU (3) | HUE070333T2 (OSRAM) |
| IL (2) | IL183930A0 (OSRAM) |
| LT (3) | LT3332789T (OSRAM) |
| LU (1) | LUC00064I2 (OSRAM) |
| MX (1) | MX2007007610A (OSRAM) |
| NO (1) | NO20073813L (OSRAM) |
| PL (4) | PL4070800T3 (OSRAM) |
| SG (1) | SG160391A1 (OSRAM) |
| SI (3) | SI2805723T1 (OSRAM) |
| WO (1) | WO2006067141A1 (OSRAM) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2805723T3 (da) | 2004-12-22 | 2018-01-29 | Merck Serono Sa | Cladribin-regime til behandling af multipel sclerose |
| CA2649810A1 (en) * | 2006-05-24 | 2007-11-29 | Laboratoires Serono S.A. | Cladribine regimen for treating multiple sclerosis |
| EP2343074A1 (en) | 2009-12-23 | 2011-07-13 | Merck Serono S.A. | Use of purine analogues for treating airway diseases |
| WO2011117267A1 (en) | 2010-03-24 | 2011-09-29 | Merck Serono Sa | Cladribine treatment of multiple sclerosis in patient groups defined by genotype |
| EP2428201A1 (en) | 2010-09-08 | 2012-03-14 | Merck Serono S.A. | Oral administration of nucleoside monophosphates |
| WO2012097867A1 (en) | 2011-01-18 | 2012-07-26 | Synthon Bv | Cladribine particles and pharmaceutical compositions comprising them |
| GB201401465D0 (en) * | 2014-01-29 | 2014-03-12 | Roach Arthur H | Use of cladribine for treating autoimmune inflammatory disease |
| GB2564717A (en) * | 2017-07-21 | 2019-01-23 | Chord Therapeutics S A R L | Use of cladribine for treating autoimmune neuromuscular disease |
| KR20250005506A (ko) | 2017-11-24 | 2025-01-09 | 메르크 파텐트 게엠베하 | 진행 형태의 다발성 경화증의 치료에서 사용을 위한 클라드리빈 용법 |
| GB2601786A (en) | 2020-12-10 | 2022-06-15 | Chord Therapeutics S A R L | Use of cladribine for treating immune brain disease |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1269659A (en) | 1984-08-06 | 1990-05-29 | Brigham Young University | Method for the production of 2'-deoxyadenosine compounds |
| US5310732A (en) * | 1986-02-03 | 1994-05-10 | The Scripps Research Institute | 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis |
| US4964848A (en) * | 1988-06-27 | 1990-10-23 | Bloom Philip M | Treatment of multiple sclerosis with lymphocytapheresis and chemo-immunosuppression |
| US5208327A (en) | 1991-12-18 | 1993-05-04 | Ortho Pharmaceutical Corporation | Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine |
| US5641757A (en) | 1994-12-21 | 1997-06-24 | Ortho Pharmaceutical Corporation | Stable 2-chloro-2'-deoxyadenosine formulations |
| CA2208484C (en) | 1994-12-22 | 2008-09-23 | Ortho Pharmaceutical Corporation | Soluble 2-chloro-2'-deoxyadenosine formulations |
| US6194395B1 (en) | 1999-02-25 | 2001-02-27 | Orthro-Mcneil Pharmaceutical, Inc. | Cyclodextrin cladribine formulations |
| WO2000064918A1 (en) | 1999-04-28 | 2000-11-02 | Sterrenbeld Biotechnologie North America, Inc. | METHOD FOR THE PRODUCTION OF 2-CHLORO-2'-DEOXYADENOSINE (CLADRIBINE) AND ITS 3,5-DI-O-p-TOLUOYL DERIVATIVE |
| DE10237146A1 (de) * | 2002-08-13 | 2004-03-04 | Medac Gesellschaft für klinische Spezialpräparate mbH | Verwendung von Treosulfan und Derivaten davon zur Behandlung der Multiplen Sklerose |
| JP4757632B2 (ja) | 2002-09-25 | 2011-08-24 | ブリガム ヤング ユニバーシティー | ２’−デオキシグアノシンから２−クロロ−２’−デオキシアデノシンを調製する方法 |
| GB2394658A (en) * | 2002-11-01 | 2004-05-05 | Cancer Rec Tech Ltd | Oral anti-cancer composition |
| WO2004075903A1 (en) * | 2003-02-25 | 2004-09-10 | Applied Research Systems Ars Holding N.V. | Combined use of ribavirin and interferon beta in demyelinating diseases |
| CA2520522C (en) | 2003-03-28 | 2012-05-29 | Ivax Corporation | Cladribine formulations for improved oral and transmucosal delivery |
| US7888328B2 (en) | 2003-03-28 | 2011-02-15 | Ares Trading S.A. | Oral formulations of cladribine |
| DK2805723T3 (da) | 2004-12-22 | 2018-01-29 | Merck Serono Sa | Cladribin-regime til behandling af multipel sclerose |
| CA2649810A1 (en) * | 2006-05-24 | 2007-11-29 | Laboratoires Serono S.A. | Cladribine regimen for treating multiple sclerosis |
-
2005
- 2005-12-20 DK DK14001970.4T patent/DK2805723T3/da active
- 2005-12-20 EP EP14001970.4A patent/EP2805723B1/en not_active Revoked
- 2005-12-20 HU HUE22166610A patent/HUE070333T2/hu unknown
- 2005-12-20 HU HUE18151634A patent/HUE059133T2/hu unknown
- 2005-12-20 EP EP05823474A patent/EP1827461B1/en not_active Expired - Lifetime
- 2005-12-20 PL PL22166610.0T patent/PL4070800T3/pl unknown
- 2005-12-20 PL PL18151634.5T patent/PL3332789T3/pl unknown
- 2005-12-20 KR KR1020077016508A patent/KR20070091662A/ko not_active Ceased
- 2005-12-20 CA CA2588966A patent/CA2588966C/en not_active Expired - Lifetime
- 2005-12-20 SI SI200532191T patent/SI2805723T1/en unknown
- 2005-12-20 LT LTEP18151634.5T patent/LT3332789T/lt unknown
- 2005-12-20 JP JP2007547486A patent/JP5795456B2/ja not_active Expired - Lifetime
- 2005-12-20 EA EA200701221A patent/EA015799B1/ru active Protection Beyond IP Right Term
- 2005-12-20 EP EP24206496.2A patent/EP4523753A3/en active Pending
- 2005-12-20 ES ES18151634T patent/ES2921858T3/es not_active Expired - Lifetime
- 2005-12-20 WO PCT/EP2005/056954 patent/WO2006067141A1/en not_active Ceased
- 2005-12-20 FI FIEP22166610.0T patent/FI4070800T3/fi active
- 2005-12-20 ES ES22166610T patent/ES3007339T3/es not_active Expired - Lifetime
- 2005-12-20 CA CA3087419A patent/CA3087419C/en not_active Expired - Lifetime
- 2005-12-20 EP EP10182632.9A patent/EP2275110B1/en not_active Expired - Lifetime
- 2005-12-20 SG SG201001736-6A patent/SG160391A1/en unknown
- 2005-12-20 DK DK22166610.0T patent/DK4070800T3/da active
- 2005-12-20 LT LTEP22166610.0T patent/LT4070800T/lt unknown
- 2005-12-20 MX MX2007007610A patent/MX2007007610A/es unknown
- 2005-12-20 HR HR20120228T patent/HRP20120228T1/hr unknown
- 2005-12-20 EP EP18151634.5A patent/EP3332789B1/en not_active Expired - Lifetime
- 2005-12-20 EP EP10182676.6A patent/EP2263678B1/en not_active Expired - Lifetime
- 2005-12-20 DK DK18151634.5T patent/DK3332789T3/da active
- 2005-12-20 SI SI200532305T patent/SI3332789T1/sl unknown
- 2005-12-20 SI SI200532321T patent/SI4070800T1/sl unknown
- 2005-12-20 BR BRPI0517132A patent/BRPI0517132B8/pt active IP Right Grant
- 2005-12-20 PL PL05823474T patent/PL1827461T3/pl unknown
- 2005-12-20 AU AU2005318190A patent/AU2005318190B2/en not_active Expired
- 2005-12-20 EP EP22166610.0A patent/EP4070800B1/en not_active Expired - Lifetime
- 2005-12-20 US US11/722,018 patent/US7713947B2/en active Active
- 2005-12-20 PL PL14001970T patent/PL2805723T3/pl unknown
- 2005-12-21 AR ARP050105411A patent/AR052830A1/es not_active Application Discontinuation
-
2007
- 2007-06-14 IL IL183930A patent/IL183930A0/en active IP Right Grant
- 2007-07-20 NO NO20073813A patent/NO20073813L/no not_active Application Discontinuation
-
2010
- 2010-04-23 US US12/766,173 patent/US8377903B2/en active Active
-
2011
- 2011-02-23 AU AU2011200768A patent/AU2011200768B2/en not_active Expired
- 2011-04-17 IL IL212421A patent/IL212421A/en active IP Right Grant
-
2012
- 2012-04-11 CY CY20121100358T patent/CY1112614T1/el unknown
-
2013
- 2013-05-30 JP JP2013113850A patent/JP5908863B2/ja not_active Expired - Lifetime
-
2015
- 2015-06-16 JP JP2015120875A patent/JP6092945B2/ja not_active Expired - Lifetime
-
2016
- 2016-04-08 JP JP2016078293A patent/JP6290962B2/ja not_active Expired - Lifetime
-
2017
- 2017-02-09 JP JP2017022375A patent/JP6430554B2/ja not_active Expired - Lifetime
-
2018
- 2018-01-18 CY CY20181100065T patent/CY1119790T1/el unknown
- 2018-02-12 LU LU00064C patent/LUC00064I2/fr unknown
- 2018-02-14 FR FR18C1008C patent/FR18C1008I2/fr active Active
- 2018-02-15 HU HUS1800009C patent/HUS1800009I1/hu unknown
- 2018-02-20 LT LTPA2018503C patent/LTC2805723I2/lt unknown
- 2018-02-28 CY CY2018006C patent/CY2018006I2/el unknown
- 2018-07-09 JP JP2018129918A patent/JP2018165271A/ja active Pending
-
2020
- 2020-08-06 JP JP2020134010A patent/JP2020193206A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200900347B (en) | Preparation of pharmaceutical compositions | |
| IL184114A0 (en) | Use of diketodithiopiperazine antibiotics for the preparation of antiangiogenic pharmaceutical compositions | |
| IL223545A0 (en) | Pharmaceutical compositions | |
| IL179809A0 (en) | Pharmaceutical compositions | |
| IL195491A (en) | Pharmaceutical preparations containing tmc278 and processes for their preparation | |
| GB0408308D0 (en) | Pharmaceutical compositions | |
| IL193894A0 (en) | Pharmaceutical compositions containing luliconazole for external use | |
| ZA200701557B (en) | Pharmaceutical compositions comprising diclofenac | |
| IL183930A0 (en) | Use of cladribine for preparation of pharmaceutical compositions | |
| IL189614A0 (en) | Pharmaceutical compositions of telmisartan | |
| IL187748A0 (en) | Pharmaceutical compositions containing misoprostal | |
| IL181827A0 (en) | Donepezil salts suitable for the preparation of pharmaceutical compositions | |
| GB0405033D0 (en) | Novel pharmaceutical compositions | |
| IL185197A0 (en) | Ophthalmological pharmaceutical compositions | |
| EP1938842A4 (en) | METHOD FOR PRODUCING A PHARMACEUTICAL COMPOSITION COMPRISING IMPROVED CRASHING CHARACTERISTICS | |
| GB0406378D0 (en) | Novel pharmaceutical compositions | |
| GB0608724D0 (en) | Novel Pharmaceutical Compositions | |
| PL1837019T3 (pl) | Kompozycja farmaceutyczna rozpadająca się w ustach | |
| GB0406380D0 (en) | Novel pharmaceutical compositions | |
| EP1805154A4 (en) | PHARMACEUTICAL COMPOSITIONS | |
| IL179337A0 (en) | Pharmaceutical compositions for the treatment of pruritus | |
| IL198634A0 (en) | Novel compounds, pharmaceutical compositions containing same, and methods of use for same | |
| PT2474528E (pt) | Compostos antineoplásicos e composições farmacêuticas dos mesmos | |
| GB0407351D0 (en) | Pharmaceutical compositions | |
| GB0400971D0 (en) | Pharmaceutical compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed |